It is an announcement many interventional cardiologists have been waiting to hear for a long time. 

The AHA Mission: Lifeline Program was designed to reduce STEMI patient transfer times, but response times still often lag, and new protocols may be needed to expedite STAT transfers.

The acquisition includes an initial investment of $35 million and an upfront closing payment of $200 million. By 2029, if the companies reach all targeted regulatory and commercial milestones, the acquisition could cost Cordis up to $1.135 billion in all.

Two-year outcomes of a QFR-guided vessel and lesion selection strategy showed that the benefits of QFR guidance continued to accrue over time compared with standard angiography guidance in patients undergoing PCI.

Read our review of some of the biggest FDA-related stories that have hit cardiology in the last month, including news from Viz.ai, Edwards Lifesciences, Abiomed and Medtronic. 

The standard-of-care thinking on TAVR has shifted from getting a valve implanted and managing immediate complications to looking decades down the road and considering the patient's long-term health. 

Charles Davidson, MD, clinical chief of cardiology and medical director of the Bluhm Cardiovascular Institute, Northwestern University, explains what hospitals need to consider when starting a new structural heart program. 

A new study reveals the damage caused to cardiovascular programs by the COVID-19 pandemic will continue to accrue unless mitigation strategies are implemented quickly. The review found a number of people dying are at home from heart conditions.